Literature DB >> 2604011

Structure-function analyses of brain angiotensin control of pressor action in rats.

J W Wright1, L L Jensen, K A Roberts, M F Sardinia, J W Harding.   

Abstract

The present investigation examined the relative pressor potencies of intracerebroventricularly infused angiotensin (ANG) II, successively shortened COOH-terminal fragments through ANG II(5-8), and the analogues [Sar1]ANG II through [Sar1]ANG II(5-8). The results indicate that ANG II, ANG III, [Sar1]ANG II, and [Sar1]ANG III were identical with respect to pressor responses in the alert free-moving rat. In addition, ANG II(3-8) and [Sar1]ANG II(3-8) exhibited 68-70% of the activity of the above compounds, whereas the activity of the shorter COOH-terminal fragments dropped to approximately 13-35%. Pressor responses caused by each of the active forms of angiotensin could be substantially reduced by pretreatment with the specific angiotensin receptor antagonist [Sar1,Thr8]ANG II (Sarthran), suggesting either that these ligands are acting at multiple receptors for ANG II and its fragments, which are all blocked by Sarthran, or that the ligands are acting at a common receptor site. These results, coupled with other recent findings, suggest that the brain angiotensin receptor may be designed to preferentially interact with ANG II and/or ANG III or other angiotensin analogues that structurally resemble ANG III such as [Sar1]ANG II. It is concluded that ANG III's importance as a centrally active ligand has been underestimated and that ANG III may be an active form of angiotensin in the brain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2604011     DOI: 10.1152/ajpregu.1989.257.6.R1551

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

2.  Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.

Authors:  S Zini; M C Fournie-Zaluski; E Chauvel; B P Roques; P Corvol; C Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Aminopeptidase A inhibitors as potential central antihypertensive agents.

Authors:  A Reaux; M C Fournie-Zaluski; C David; S Zini; B P Roques; P Corvol; C Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 4.  Role of angiotensin III in hypertension.

Authors:  Annabelle Reaux-Le Goazigo; Xavier Iturrioz; Celine Fassot; Cedric Claperon; Bernard P Roques; Catherine Llorens-Cortes
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

5.  The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.

Authors:  B J Yamamoto; P D Elias; J A Masino; B D Hudson; A T McCoy; Z J Anderson; M D Varnum; M F Sardinia; J W Wright; J W Harding
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

6.  Modulation by nitric oxide and prostaglandin of the renal vascular response to angiotensin II (3-8).

Authors:  M Yoshida; M Kikukawa; H Hisa; S Satoh
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 7.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

Review 8.  Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials.

Authors:  Sara Abdulrahman Alomar; Sarah Ali Alghabban; Hadeel Abdulaziz Alharbi; Mehad Fahad Almoqati; Yazid Alduraibi; Ahmed Abu-Zaid
Journal:  Avicenna J Med       Date:  2021-01-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.